Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS trial of intravenous anifrolumab in active proliferative lupus nephritis
jRCT2011210060Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Anifrolumab with Placebo (2 arms). Primary endpoint: Complete Renal Response. Started Aug 2022; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011210060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210060.